Navigation Links
Evotec Expands Collaboration With InterMune
Date:3/6/2008

Fragment-Based Drug Discovery Program Yields Results and Leads to Expansion

of Collaboration

HAMBURG, Germany and OXFORD, England, March 6 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a second drug discovery contract with Evotec.

Evotec will support InterMune's research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further characterize active compounds and optimize their potency and selectivity to generate lead molecules for subsequent progression into clinical trials.

This contract expands Evotec's existing collaboration with InterMune which was initiated in early 2007. This collaboration applies Evotec's fragment-based drug discovery platform, EVOlution(TM), in combination with their ultra-high-throughput screening (uHTS) technologies to InterMune's targets. To date new lead series have been identified for further optimization. Evotec also provides medicinal chemistry, secondary screening, protein production, X-ray crystallography and ADMET. The financial terms include a technology access fee for access to Evotec's fragment-based drug discovery platform, EVOlutionTM, plus ongoing research funding.

"With the support of Evotec, InterMune has made considerable progress in their Hepatitis C drug discovery and development program. We are pleased that InterMune saw the value in our proprietary fragment-based drug discovery technology and that it has contributed to the success to their research efforts," said Dr Mark Ashton, Executive Vice President Business Development Services at Evotec.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements includ
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
10. Evotec Starts Phase II in Smoking Cessation with EVT 302
11. ATS Medical Expands Open Pivot Heart Valve Offerings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Conferences in ... October ... OREX ), a biopharmaceutical company focused on the treatment,of obesity and ... for October 2008, which includes,six data presentations and one sponsored symposium ...
... Germany, Sept. 29 Nomad Bioscience GmbH,announces ... agreement with Bayer,Innovation GmbH and Icon Genetics ... technology platforms, including its transient expression,technology magnICON(R), ... in green plants. The agreement provides,Nomad with ...
... Cooperation with Kentucky Bioprocessing for future-oriented technology, ... 29 Bayer,Innovation GmbH and Kentucky Bioprocessing, ... at KBP,s Owensboro plant in the US ... biopharmaceuticals. Based on Bayer,s proprietary,magnICON(R) technology, plant ...
Cached Biology Technology:Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting 2Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 2Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 3Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 4
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... harness the energy of ATP (or GTP, a related ... examples of motors include myosin and dynein, proteins that ... of actin or tubulin proteins. The ATP-dependent assembly of ... motor: for instance, the march of white blood cells ...
... Bork, Ph.D., Senior Bioinformatics Scientist at the European Molecular ... that they have identified a new primate-specific gene family ... of eight family members, the RGP gene cluster may ... primates from the rest of the animal kingdom. , ...
... scientists has,found the first clear evidence that the ... recognize and respond to a million,different proteins might ... apparent function is to jump around in genetic ... the genetic material, and scientists,have suspected that this ...
Cached Biology News:DNA Recombination and Repair—A New Twist to RecA Function 2Scientists document complex genomic events leading to the birth of new genes 2Scientists document complex genomic events leading to the birth of new genes 3Jumping gene helps explain immune system's abilities 2Jumping gene helps explain immune system's abilities 3